Eli Lilly Bolsters CAR T-Cell Immunotherapy Pipeline With Kelonia Acquisition – And It’s Paying $7B

• Kelonia shareholders will receive up to $7 billion, including $3.25 billion upfront, with additional payments tied to milestones.
• Kelonia’s lead candidate, KLN-1010, for multiple myeloma, has shown promising early results in the Phase 1 clinical trials.
• The deal is expected to close in the second half of 2026.

Eli Lilly and Company (LLY) on Monday agreed to acquire Kelonia Therapeutics in a deal worth up to $7 billion, as the drugmaker moves to strengthen its oncology pipeline and expand its presence in the fast-growing cancer treatment market.

LLY shares traded 0.1% lower at the time of writing, after declining in five of the past six sessions.

Lilly Gets Access To Kelonia’s CAR-T Cell Programs

The acquisition will give Lilly access to Kelonia’s gene therapy platform and Chimeric Antigen Receptor (CAR)-T cell immunotherapy programs. CAR-T therapies involve delivering genes or genetically engineered cells to help a patient's immune system fight cancer.

Kelonia’s lead candidate, KLN-1010, is being tested for multiple myeloma and has shown promising early results in the Phase 1 clinical trials.

Under the agreement, Kelonia shareholders could receive up to $7 billion, including $3.25 billion upfront, with additional payments tied to milestones. The deal is expected to close in the second half of 2026.

“We look forward to working together with the Kelonia team to rapidly advance KLN-1010 to address patient need and recognize the full potential of their platform in other conditions where patients may benefit,” said Jacob Van Naarden, executive vice president and president of Lilly Oncology.

Addition To Orna Acquisition

Lilly has been bolstering its cell therapy pipeline this year. In February, the pharmaceutical giant signed an agreement to acquire Orna Therapeutics for up to $2.4 billion in cash.

Orna’s lead candidate, ORN-252, is a clinical trial-ready CAR-T therapy targeting CD19, a critical cell-surface protein used to treat autoimmune diseases.

The latest deal will strengthen Lilly’s cancer treatment pipeline, which includes, among others, the blood cancer therapy Jaypirca and the breast cancer drug Verzenio.

How Did Retail Traders React?

Retail sentiment on Stocktwits remained in the ‘neutral’ zone over the past 24 hours.

One user highlighted the potential of the vast global market opportunity.

Another user said Lilly is reinforcing its dominance in advanced biologics.

Year to date, the stock has shed around 14%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.